DaVita Management

Management criteria checks 4/4

DaVita's CEO is Javier Rodriguez, appointed in Jun 2019, has a tenure of 4.83 years. total yearly compensation is $2.98M, comprised of 40.2% salary and 59.8% bonuses, including company stock and options. directly owns 0.8% of the company’s shares, worth $93.46M. The average tenure of the management team and the board of directors is 5.7 years and 4.8 years respectively.

Key information

Javier Rodriguez

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage	40.2%
CEO tenure	4.8yrs
CEO ownership	0.8%
Management average tenure	5.7yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

DaVita Stock Is A Hold As It Expands In Latin America

Mar 18

Market Might Still Lack Some Conviction On DaVita Inc. (NYSE:DVA) Even After 27% Share Price Boost

Mar 13

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Mar 04

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 16

DaVita could benefit from legislation that would return dialysis protection to Medicare

Aug 16

We Think DaVita (NYSE:DVA) Is Taking Some Risk With Its Debt

Aug 14

DaVita stock dips as peer Fresenius outlook weighed down by labor cost, inflation

Jul 28

DaVita: Valuation Turning Attractive

Jul 16

Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?

Jul 13

Here's Why I Think DaVita (NYSE:DVA) Is An Interesting Stock

May 15

DaVita Offers Stability During Market Volatility

May 12

Here's Why DaVita (NYSE:DVA) Has A Meaningful Debt Burden

Apr 29

Is It Time To Consider Buying DaVita Inc. (NYSE:DVA)?

Apr 14

DaVita's Wide Moat Is Undervalued

Feb 11

Do DaVita's (NYSE:DVA) Earnings Warrant Your Attention?

Feb 11

DaVita (NYSE:DVA) Has A Pretty Healthy Balance Sheet

Jan 29

When Should You Buy DaVita Inc. (NYSE:DVA)?

Jan 14

CEO Compensation Analysis

How has Javier Rodriguez's remuneration changed compared to DaVita's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	US$692m
Sep 30 2023	n/a	n/a	US$596m
Jun 30 2023	n/a	n/a	US$454m
Mar 31 2023	n/a	n/a	US$500m
Dec 31 2022	US$3m	US$1m	US$547m
Sep 30 2022	n/a	n/a	US$680m
Jun 30 2022	n/a	n/a	US$834m
Mar 31 2022	n/a	n/a	US$903m
Dec 31 2021	US$3m	US$1m	US$978m
Sep 30 2021	n/a	n/a	US$984m
Jun 30 2021	n/a	n/a	US$883m
Mar 31 2021	n/a	n/a	US$791m
Dec 31 2020	US$73m	US$1m	US$783m
Sep 30 2020	n/a	n/a	US$832m
Jun 30 2020	n/a	n/a	US$824m
Mar 31 2020	n/a	n/a	US$816m
Dec 31 2019	US$17m	US$1m	US$705m
Sep 30 2019	n/a	n/a	US$623m
Jun 30 2019	n/a	n/a	US$548m
Mar 31 2019	n/a	n/a	US$551m
Dec 31 2018	US$8m	US$900k	US$616m
Sep 30 2018	n/a	n/a	US$617m
Jun 30 2018	n/a	n/a	US$698m
Mar 31 2018	n/a	n/a	US$652m
Dec 31 2017	US$8m	US$900k	US$909m

Compensation vs Market: Javier's total compensation ($USD2.98M) is below average for companies of similar size in the US market ($USD13.51M).

Compensation vs Earnings: Javier's compensation has been consistent with company performance over the past year.

CEO

Javier Rodriguez (52 yo)

4.8yrs

Tenure

US$2,984,581

Compensation

Mr. Javier J. Rodriguez serves as an Independent Director at Gilead Sciences, Inc. since June 15, 2020. He has been Chief Executive Officer and Executive Director of DaVita Inc. since June 1, 2019. Mr. Rod...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Javier Rodriguez	CEO & Executive Director	4.8yrs	US$2.98m	0.80% $ 93.5m
Joel Ackerman	CFO & Treasurer	7.2yrs	US$4.70m	0.16% $ 18.7m
Kathleen Waters	Chief Legal & Public Affairs Officer	7.9yrs	US$3.53m	0.068% $ 7.9m
James Hearty	Chief Compliance Officer	6.1yrs	US$1.66m	0.014% $ 1.6m
Michael Staffieri	Chief Operating Officer of Kidney Care	10.1yrs	US$6.92m	0.23% $ 26.8m
Christopher Berry	Group VP & Chief Accounting Officer	less than a year	no data	no data
Jim Gustafson	Vice President of Investor Relations	no data	no data	no data
Kenneth Smith	Chief People Officer	no data	no data	no data
Misha Palecek	Chief Transformation Officer of U.S. Kidney Care Business	no data	no data	no data
Jeffrey Giullian	Chief Medical Officer of Kidney Care	4.2yrs	no data	no data
Partha Das	Chief Medical Officer of DaVita International	5.7yrs	no data	no data
Mandy Hale	Chief Nursing Officer	3.8yrs	no data	no data

5.7yrs

Average Tenure

52yo

Average Age

Experienced Management: DVA's management team is seasoned and experienced (5.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Javier Rodriguez	CEO & Executive Director	4.8yrs	US$2.98m	0.80% $ 93.5m
John Nehra	Independent Director	23.4yrs	US$345.49k	0.089% $ 10.4m
Charles Berg	Director	17.1yrs	US$284.97k	0.029% $ 3.4m
Barbara Desoer	Independent Director	8.5yrs	US$367.47k	0.018% $ 2.1m
Phyllis Yale	Independent Director	7.8yrs	US$329.97k	0.017% $ 2.0m
Wendy Schoppert	Independent Director	less than a year	no data	0.00094% $ 109.5k
Pamela Arway	Independent Chair	14.9yrs	US$469.97k	0.027% $ 3.2m
Dennis Pullin	Independent Director	no data	no data	no data
Adam Schechter	Independent Director	1.6yrs	US$37.86k	0.0030% $ 348.2k
Jason Hollar	Independent Director	1.9yrs	US$144.10k	0.0040% $ 469.3k
Gregory Moore	Independent Director	2.6yrs	US$294.97k	0.0054% $ 629.9k

4.8yrs

Average Tenure

63yo

Average Age

Experienced Board: DVA's board of directors are considered experienced (4.8 years average tenure).

DaVita Management

Management criteria checks 4/4

Key information

Recent management updates

Davita Announces Dennis Pullin to Its Board of Directors

Chief Operating Officer of Kidney Care exercised options and sold US$3.0m worth of stock

CEO & Executive Director exercised options and sold US$36m worth of stock

Chief Compliance Officer recently sold US$3.0m worth of stock

Chief Compliance Officer notifies of intention to sell stock

CEO & Executive Director exercised options and sold US$16m worth of stock

Recent updates

DaVita Inc. to Report Q1, 2024 Results on May 02, 2024

Davita Announces Dennis Pullin to Its Board of Directors

DaVita Stock Is A Hold As It Expands In Latin America

Chief Operating Officer of Kidney Care exercised options and sold US$3.0m worth of stock

Market Might Still Lack Some Conviction On DaVita Inc. (NYSE:DVA) Even After 27% Share Price Boost

CEO & Executive Director exercised options and sold US$36m worth of stock

Price target increased by 7.4% to US$131

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Chief Compliance Officer recently sold US$3.0m worth of stock

Chief Compliance Officer notifies of intention to sell stock

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Price target increased by 14% to US$120

Is DaVita (NYSE:DVA) Using Too Much Debt?

DaVita Inc. to Report Q4, 2023 Results on Feb 13, 2024

DaVita: Assessing After The Rally

DaVita Inc.'s (NYSE:DVA) Subdued P/E Might Signal An Opportunity

CEO & Executive Director exercised options and sold US$16m worth of stock

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 13%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

DaVita (NYSE:DVA) Has A Somewhat Strained Balance Sheet

DaVita: Simple And Compelling After Sell-Off

Returns On Capital Signal Difficult Times Ahead For DaVita (NYSE:DVA)

DaVita Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investor sentiment deteriorates as stock falls 19%

DaVita: Continued Economic Hurdles, Market Expectations May Be Correct

Chief Legal & Public Affairs Officer notifies of intention to sell stock

Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?

Price target increased by 7.3% to US$113

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

DaVita (NYSE:DVA) Takes On Some Risk With Its Use Of Debt

DaVita Inc. Announces Management Changes

DaVita: Breakout Not Supported Without Leverage Effects, Reiterate Hold

Returns At DaVita (NYSE:DVA) Appear To Be Weighed Down

DaVita Inc. to Report Q2, 2023 Results on Aug 03, 2023

DaVita Inc. (NYSE:DVA) Shares Could Be 41% Below Their Intrinsic Value Estimate

Chief Legal & Public Affairs Officer recently sold US$1.0m worth of stock

CEO & Executive Director notifies of intention to sell stock

Price target increased by 8.1% to US$96.27

Price target increased by 8.3% to US$94.38

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

What Is DaVita Inc.'s (NYSE:DVA) Share Price Doing?

Price target increased by 8.6% to US$88.80

These 4 Measures Indicate That DaVita (NYSE:DVA) Is Using Debt Extensively

Investors Met With Slowing Returns on Capital At DaVita (NYSE:DVA)

Director recently sold US$108k worth of stock

Are Investors Undervaluing DaVita Inc. (NYSE:DVA) By 40%?

Director exercised options and sold US$106k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 7.0% to US$86.50

DaVita HealthCare Partners Q4 2022 Earnings Preview

Moon Capital - DaVita: A Recession-Resistant Cash Generating Machine

DaVita Inc. to Report Q4, 2022 Results on Feb 22, 2023

Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?

Is DaVita (NYSE:DVA) A Risky Investment?

DaVita: Shares Still Appear Cheap After Outlook Cut, Technicals Suggest Caution

Consensus EPS estimates fall by 21%

Independent Director recently bought US$356k worth of stock

Price target decreased to US$83.57

Third quarter 2022 earnings: EPS misses analyst expectations

DaVita Q3 2022 Earnings Preview

Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?

DaVita Inc. to Report Q3, 2022 Results on Oct 28, 2022

DaVita: Solid Valuation And Cash Flow, Price Recovering After SCOTUS Ruling

DaVita Inc. Appoints Adam H. Schechter to Board of Directors

DaVita could benefit from legislation that would return dialysis protection to Medicare

We Think DaVita (NYSE:DVA) Is Taking Some Risk With Its Debt

Second quarter 2022 earnings: EPS exceeds analyst expectations